Lv4
414 积分 2025-11-01 加入
Early on-treatment LSM reliably predicts liver-related events in CHB patients with significant fibrosis and cirrhosis
2天前
已完结
Persistent steatosis correlates with decreased fibrosis regression during anti-HBV treatment in patients with chronic HBV infection
23天前
已完结
Comparison of diagnostic accuracy and utility of non-invasive tests for clinically significant liver disease in a general population with metabolic dysfunction
30天前
已完结
A reasonably likely surrogate endpoint for metabolic dysfunction–associated steatohepatitis
1个月前
已完结
ADAPT: An Algorithm Incorporating PRO‐C3 Accurately Identifies Patients With NAFLD and Advanced Fibrosis
1个月前
已完结
Accuracy of the enhanced liver fibrosis test in patients with type 2 diabetes mellitus and its clinical implications
1个月前
已完结
Ability of soluble TREM2 and PRO-C3 as biomarkers to predict changes in MASLD activity
1个月前
已完结
Diagnosis and Monitoring of Nonalcoholic Steatohepatitis: Current State and Future Directions
1个月前
已完结
Thrombospondin-2 is a performant biomarker of at-risk MASH and advanced MASH fibrosis in a large multicentre European cohort
1个月前
已完结
TERN-501 monotherapy and combination therapy with TERN-101 in metabolic dysfunction-associated steatohepatitis: the randomized phase 2a DUET trial
1个月前
已完结